Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-01-07

AUTHORS

Reeti Joshi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Yujin Park, Prashanth Sunkureddi

ABSTRACT

OBJECTIVES: To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice. METHODS: This descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected. RESULTS: Medical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic naïve. The most common reasons for secukinumab initiation among biologic-naïve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150 mg every week (39.7%), 300 mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received ≥ 1 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150 mg and 300 mg, respectively, every 4 weeks. CONCLUSIONS: In this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic naïve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab. More... »

PAGES

1-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9

DOI

http://dx.doi.org/10.1007/s40801-018-0146-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111241892

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30617811


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine, Houston, TX USA", 
          "id": "http://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Baylor College of Medicine, Houston, TX USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joshi", 
        "givenName": "Reeti", 
        "id": "sg:person.014176477447.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014176477447.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Montreal, QC Canada", 
          "id": "http://www.grid.ac/institutes/grid.487188.a", 
          "name": [
            "Analysis Group, Inc., Montreal, QC Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Latremouille-Viau", 
        "givenName": "Dominick", 
        "id": "sg:person.01245200117.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245200117.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Boston, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.417986.5", 
          "name": [
            "Analysis Group, Inc., Boston, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meiselbach", 
        "givenName": "Mark K.", 
        "id": "sg:person.015345301707.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015345301707.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Los Angeles, CA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Analysis Group, Inc., Los Angeles, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Jipan", 
        "id": "sg:person.01151424673.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Yujin", 
        "id": "sg:person.01176534524.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176534524.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Texas Medical Branch, Galveston, TX USA", 
          "id": "http://www.grid.ac/institutes/grid.176731.5", 
          "name": [
            "University of Texas Medical Branch, Galveston, TX USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sunkureddi", 
        "givenName": "Prashanth", 
        "id": "sg:person.0655601370.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655601370.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-016-3231-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022348277", 
          "https://doi.org/10.1007/s10067-016-3231-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-018-4112-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103626320", 
          "https://doi.org/10.1007/s10067-018-4112-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-016-0969-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042895881", 
          "https://doi.org/10.1186/s13075-016-0969-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-017-1490-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922896", 
          "https://doi.org/10.1186/s13075-017-1490-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-015-2958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052577864", 
          "https://doi.org/10.1007/s10067-015-2958-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01-07", 
    "datePublishedReg": "2019-01-07", 
    "description": "OBJECTIVES: To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.\nMETHODS: This descriptive analysis of data from a US retrospective medical chart review included patients aged\u2009\u2265\u200918\u00a0years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected.\nRESULTS: Medical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic na\u00efve. The most common reasons for secukinumab initiation among biologic-na\u00efve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150\u00a0mg every week (39.7%), 300\u00a0mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received\u2009\u2265\u20091 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150\u00a0mg and 300\u00a0mg, respectively, every 4\u00a0weeks.\nCONCLUSIONS: In this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic na\u00efve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0146-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "medical chart review", 
      "retrospective medical chart review", 
      "efficacy/effectiveness", 
      "chart review", 
      "biologic-na\u00efve", 
      "medical charts", 
      "common reason", 
      "physician-level characteristics", 
      "biologic-experienced patients", 
      "characterization of patients", 
      "co-morbidity profile", 
      "prior biologics", 
      "secukinumab dose", 
      "index date", 
      "patient demographics", 
      "loading dose", 
      "US patients", 
      "disease characteristics", 
      "mean age", 
      "secukinumab", 
      "physician survey", 
      "patients", 
      "treatment history", 
      "clinical practice", 
      "weeks", 
      "rheumatologists", 
      "spondylitis", 
      "one-third", 
      "dose", 
      "biologics", 
      "na\u00efve", 
      "prescription", 
      "treatment", 
      "descriptive analysis", 
      "review", 
      "failure", 
      "dosing", 
      "years", 
      "charts", 
      "demographics", 
      "AS", 
      "age", 
      "date", 
      "initiation", 
      "reasons", 
      "history", 
      "effectiveness", 
      "online form", 
      "survey", 
      "profile", 
      "characteristics", 
      "practice", 
      "data", 
      "analysis", 
      "information", 
      "form", 
      "characterization", 
      "rheumatologist-reported reasons", 
      "US retrospective medical chart review", 
      "Eligible rheumatologists", 
      "first secukinumab prescription", 
      "secukinumab prescription", 
      "secukinumab initiation", 
      "maintenance secukinumab dose", 
      "US medical chart review", 
      "secukinumab efficacy/effectiveness", 
      "US Physician Survey"
    ], 
    "name": "Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review", 
    "pagination": "1-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111241892"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0146-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30617811"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0146-9", 
      "https://app.dimensions.ai/details/publication/pub.1111241892"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_800.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0146-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      22 PREDICATES      98 URIs      85 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0146-9 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Nc02e14e968df4e9f9d518f9fc1fab54a
4 schema:citation sg:pub.10.1007/s10067-015-2958-2
5 sg:pub.10.1007/s10067-016-3231-z
6 sg:pub.10.1007/s10067-018-4112-4
7 sg:pub.10.1186/s13075-016-0969-2
8 sg:pub.10.1186/s13075-017-1490-y
9 schema:datePublished 2019-01-07
10 schema:datePublishedReg 2019-01-07
11 schema:description OBJECTIVES: To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice. METHODS: This descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected. RESULTS: Medical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic naïve. The most common reasons for secukinumab initiation among biologic-naïve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150 mg every week (39.7%), 300 mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received ≥ 1 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150 mg and 300 mg, respectively, every 4 weeks. CONCLUSIONS: In this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic naïve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree true
15 schema:isPartOf N4a6fdfc7ad9845c8b8b2ebefdcf501a4
16 N7bf11a5d9ca144c78100e20511ff8707
17 sg:journal.1051855
18 schema:keywords AS
19 Eligible rheumatologists
20 US Physician Survey
21 US medical chart review
22 US patients
23 US retrospective medical chart review
24 age
25 analysis
26 biologic-experienced patients
27 biologic-naïve
28 biologics
29 characteristics
30 characterization
31 characterization of patients
32 chart review
33 charts
34 clinical practice
35 co-morbidity profile
36 common reason
37 data
38 date
39 demographics
40 descriptive analysis
41 disease characteristics
42 dose
43 dosing
44 effectiveness
45 efficacy/effectiveness
46 failure
47 first secukinumab prescription
48 form
49 history
50 index date
51 information
52 initiation
53 loading dose
54 maintenance secukinumab dose
55 mean age
56 medical chart review
57 medical charts
58 naïve
59 one-third
60 online form
61 patient demographics
62 patients
63 physician survey
64 physician-level characteristics
65 practice
66 prescription
67 prior biologics
68 profile
69 reasons
70 retrospective medical chart review
71 review
72 rheumatologist-reported reasons
73 rheumatologists
74 secukinumab
75 secukinumab dose
76 secukinumab efficacy/effectiveness
77 secukinumab initiation
78 secukinumab prescription
79 spondylitis
80 survey
81 treatment
82 treatment history
83 weeks
84 years
85 schema:name Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
86 schema:pagination 1-9
87 schema:productId N062fda1b77614f7581809f9dc9034681
88 N4c716960bde2457c91a11184787e202c
89 Nfd18fc933857472fb5d400e00f52cd44
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111241892
91 https://doi.org/10.1007/s40801-018-0146-9
92 schema:sdDatePublished 2022-01-01T18:51
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nfa959b4f5944441a9a5e5e140708d500
95 schema:url https://doi.org/10.1007/s40801-018-0146-9
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N062fda1b77614f7581809f9dc9034681 schema:name pubmed_id
100 schema:value 30617811
101 rdf:type schema:PropertyValue
102 N0b8e7a0cec1342f1b7438c7d4ce65a4b rdf:first sg:person.01245200117.73
103 rdf:rest N3e006fc6530d4bc0bbe7054c030e63dd
104 N3e006fc6530d4bc0bbe7054c030e63dd rdf:first sg:person.015345301707.41
105 rdf:rest Nbf4a4cff51c246f093636e5dca46e7da
106 N4a6fdfc7ad9845c8b8b2ebefdcf501a4 schema:issueNumber 1
107 rdf:type schema:PublicationIssue
108 N4c716960bde2457c91a11184787e202c schema:name dimensions_id
109 schema:value pub.1111241892
110 rdf:type schema:PropertyValue
111 N7bf11a5d9ca144c78100e20511ff8707 schema:volumeNumber 6
112 rdf:type schema:PublicationVolume
113 N7fa4593106fa450cb70934574cc3a07e rdf:first sg:person.01176534524.25
114 rdf:rest N917a8fa0881347c08393270ac33a6b1a
115 N917a8fa0881347c08393270ac33a6b1a rdf:first sg:person.0655601370.99
116 rdf:rest rdf:nil
117 Nbf4a4cff51c246f093636e5dca46e7da rdf:first sg:person.01151424673.71
118 rdf:rest N7fa4593106fa450cb70934574cc3a07e
119 Nc02e14e968df4e9f9d518f9fc1fab54a rdf:first sg:person.014176477447.84
120 rdf:rest N0b8e7a0cec1342f1b7438c7d4ce65a4b
121 Nfa959b4f5944441a9a5e5e140708d500 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 Nfd18fc933857472fb5d400e00f52cd44 schema:name doi
124 schema:value 10.1007/s40801-018-0146-9
125 rdf:type schema:PropertyValue
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
130 schema:name Public Health and Health Services
131 rdf:type schema:DefinedTerm
132 sg:journal.1051855 schema:issn 2198-9788
133 2199-1154
134 schema:name Drugs - Real World Outcomes
135 schema:publisher Springer Nature
136 rdf:type schema:Periodical
137 sg:person.01151424673.71 schema:affiliation grid-institutes:None
138 schema:familyName Xie
139 schema:givenName Jipan
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71
141 rdf:type schema:Person
142 sg:person.01176534524.25 schema:affiliation grid-institutes:grid.418424.f
143 schema:familyName Park
144 schema:givenName Yujin
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176534524.25
146 rdf:type schema:Person
147 sg:person.01245200117.73 schema:affiliation grid-institutes:grid.487188.a
148 schema:familyName Latremouille-Viau
149 schema:givenName Dominick
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245200117.73
151 rdf:type schema:Person
152 sg:person.014176477447.84 schema:affiliation grid-institutes:grid.39382.33
153 schema:familyName Joshi
154 schema:givenName Reeti
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014176477447.84
156 rdf:type schema:Person
157 sg:person.015345301707.41 schema:affiliation grid-institutes:grid.417986.5
158 schema:familyName Meiselbach
159 schema:givenName Mark K.
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015345301707.41
161 rdf:type schema:Person
162 sg:person.0655601370.99 schema:affiliation grid-institutes:grid.176731.5
163 schema:familyName Sunkureddi
164 schema:givenName Prashanth
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655601370.99
166 rdf:type schema:Person
167 sg:pub.10.1007/s10067-015-2958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052577864
168 https://doi.org/10.1007/s10067-015-2958-2
169 rdf:type schema:CreativeWork
170 sg:pub.10.1007/s10067-016-3231-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1022348277
171 https://doi.org/10.1007/s10067-016-3231-z
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s10067-018-4112-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103626320
174 https://doi.org/10.1007/s10067-018-4112-4
175 rdf:type schema:CreativeWork
176 sg:pub.10.1186/s13075-016-0969-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042895881
177 https://doi.org/10.1186/s13075-016-0969-2
178 rdf:type schema:CreativeWork
179 sg:pub.10.1186/s13075-017-1490-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922896
180 https://doi.org/10.1186/s13075-017-1490-y
181 rdf:type schema:CreativeWork
182 grid-institutes:None schema:alternateName Analysis Group, Inc., Los Angeles, CA USA
183 schema:name Analysis Group, Inc., Los Angeles, CA USA
184 rdf:type schema:Organization
185 grid-institutes:grid.176731.5 schema:alternateName University of Texas Medical Branch, Galveston, TX USA
186 schema:name University of Texas Medical Branch, Galveston, TX USA
187 rdf:type schema:Organization
188 grid-institutes:grid.39382.33 schema:alternateName Baylor College of Medicine, Houston, TX USA
189 schema:name Baylor College of Medicine, Houston, TX USA
190 rdf:type schema:Organization
191 grid-institutes:grid.417986.5 schema:alternateName Analysis Group, Inc., Boston, MA USA
192 schema:name Analysis Group, Inc., Boston, MA USA
193 rdf:type schema:Organization
194 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation, East Hanover, NJ USA
195 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ USA
196 rdf:type schema:Organization
197 grid-institutes:grid.487188.a schema:alternateName Analysis Group, Inc., Montreal, QC Canada
198 schema:name Analysis Group, Inc., Montreal, QC Canada
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...